ProKidney director sells 757K shares at ~$1.40
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
PROKIDNEY CORP. (PROK) director Brian J. G. Pereira reported six sales of Class A Common Stock over August 18–20, 2026, totaling 757,164 shares. Sales included both direct holdings and shares held indirectly by the Brian J. G. Pereira 2012 Irrevocable Trust, at weighted average prices between $1.345 and $1.50 per share in open market or private transactions.
Insights
Analyzing...
Insider Trade Summary
Net Seller: 757,164 shares
Net Sell
6 txns
Insider
Pereira Brian JG
Role
Director
Sold
757,164 shs ($1.07M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A Common Stock F3 | 222,948 | $1.4199 | $317K |
| Sale | Class A Common Stock F3 | 27,052 | $1.4199 | $38K |
| Sale | Class A Common Stock F2 | 222,949 | $1.4407 | $321K |
| Sale | Class A Common Stock F2 | 27,051 | $1.4407 | $39K |
| Sale | Class A Common Stock F1 | 229,338 | $1.3712 | $314K |
| Sale | Class A Common Stock F1 | 27,826 | $1.3712 | $38K |
Holdings After Transaction:
Class A Common Stock — 0 shares (Indirect, By Brian J. G. Pereira 2012 Irrevocable Trust);
Class A Common Stock — 0 shares (Direct)
Footnotes (3)
- F1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.345 to $1.40, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.38 to $1.50, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.38 to $1.47, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Key Figures
Total shares sold: 757,164 shares
Shares sold August 18, 2026 (indirect): 229,338 shares
Shares sold August 18, 2026 (direct): 27,826 shares
+3 more
6 metrics
Total shares sold
757,164 shares
Aggregate net shares sold across six transactions on August 18–20, 2026
Shares sold August 18, 2026 (indirect)
229,338 shares
Class A Common Stock sold via Brian J. G. Pereira 2012 Irrevocable Trust at weighted average price
Shares sold August 18, 2026 (direct)
27,826 shares
Direct holding sale at weighted average price
Weighted average price range F1
$1.345–$1.40 per share
Price range for trades footnoted F1 on August 18, 2026
Weighted average price range F2
$1.38–$1.50 per share
Price range for trades footnoted F2 on August 19, 2026
Weighted average price range F3
$1.38–$1.47 per share
Price range for trades footnoted F3 on August 20, 2026
Key Terms
weighted average price, irrevocable trust, open market or private transaction
3 terms
weighted average price financial
"The price reported is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
irrevocable trust financial
"By Brian J. G. Pereira 2012 Irrevocable Trust"
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
open market or private transaction financial
"Sale in open market or private transaction"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did PROK director Brian Pereira report in this Form 4 for PROK?
Brian J. G. Pereira reported six sales of PROKIDNEY CORP. Class A Common Stock on August 18–20, 2026, in open market or private transactions, involving both his direct holdings and shares held by the Brian J. G. Pereira 2012 Irrevocable Trust.
Were any of Brian Pereira’s PROK trades made under a Rule 10b5-1 plan?
The filing’s 10b5-1 checkbox is marked false, and the footnotes describe weighted average pricing only. There is no indication in this Form 4 that the reported transactions were made pursuant to a Rule 10b5-1 trading plan.
What part of Brian Pereira’s PROK holdings were sold indirectly via a trust?
Several transactions are marked as indirect through the “Brian J. G. Pereira 2012 Irrevocable Trust.” On each of the three days, one sale block is attributed to the trust and a separate sale block to Pereira’s direct holdings, together totaling 757,164 shares sold.
AI-generated analysis. How Rhea-AI works. Not financial advice.
